Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q2 2021 · 10-Q
Revenue$82.94M$82.94M+6.3% vs Q2 2020 Net Income$72.84M$72.84M+804.0% vs Q2 2020 EPS Diluted$1.79$1.79+678.3% vs Q2 2020 Gross Profit$50,239,000+3.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$29,535,000−32.7% Free Cash Flowderived$28,810,000−33.0% Margins · derivedGross margin60.6%−1.4 pt vs Q2 2020
Operating margin19.8%−1.4 pt vs Q2 2020
Net margin87.8%+77.5 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 5, 2021 · 36 d after period end